Halozyme Therapeutics (HALO) Misses Q4 EPS by 9c, Offers Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/25/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Tweet
Share
E-mailGet Alerts HALO Hot Sheet
Price: $125.63 +0.88%
EPS Growth %: +32.6%
Financial Fact:
Operating income (loss): -22.74M
Today's EPS Names:
FCNCA, FCNCA, RCBC, More
EPS Growth %: +32.6%
Financial Fact:
Operating income (loss): -22.74M
Today's EPS Names:
FCNCA, FCNCA, RCBC, More
Join SI Premium – FREE
Halozyme Therapeutics (NASDAQ: HALO) reported Q4 EPS of ($0.24), $0.09 worse than the analyst estimate of ($0.15). Revenue for the quarter came in at $53.7 million versus the consensus estimate of $56.93 million.
GUIDANCE:
Halozyme Therapeutics sees FY2020 EPS of $0.60-$0.75, versus the consensus of $0.58. Halozyme Therapeutics sees FY2020 revenue of $230-245 million, versus the consensus of $220.7 million.
For earnings history and earnings-related data on Halozyme Therapeutics (HALO) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Goldman Sachs Downgrades Norsk Hydro SA (NHY:NO) (NHYDY) to Neutral
- Preferred Bank (PFBC) Tops Q3 EPS by 4c
- Infosys Limited (INFY) Reports In-Line Q3 EPS
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
